Remacemide

DB06458

small molecule investigational

Deskripsi

Struktur Molekul 2D

Berat 268.36
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

943 Data
Buprenorphine Remacemide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Remacemide.
Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Remacemide.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Remacemide.
Hydrocodone Remacemide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Remacemide.
Magnesium sulfate The therapeutic efficacy of Remacemide can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Remacemide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Remacemide may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Remacemide.
Mirtazapine Remacemide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Remacemide.
Orphenadrine Remacemide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Remacemide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Remacemide.
Pramipexole Remacemide may increase the sedative activities of Pramipexole.
Ropinirole Remacemide may increase the sedative activities of Ropinirole.
Rotigotine Remacemide may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Remacemide.
Sodium oxybate Remacemide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Remacemide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Remacemide.
Thalidomide Remacemide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Remacemide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Eliglustat The metabolism of Eliglustat can be decreased when combined with Remacemide.
Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Remacemide.
Cilostazol The metabolism of Cilostazol can be decreased when combined with Remacemide.
Colchicine The metabolism of Colchicine can be decreased when combined with Remacemide.
Fentanyl The risk or severity of CNS depression can be increased when Fentanyl is combined with Remacemide.
Iloperidone The metabolism of Iloperidone can be decreased when combined with Remacemide.
Retapamulin The metabolism of Retapamulin can be decreased when combined with Remacemide.
Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Remacemide.
Vardenafil The metabolism of Vardenafil can be decreased when combined with Remacemide.
Zopiclone The metabolism of Zopiclone can be decreased when combined with Remacemide.
Lovastatin The metabolism of Lovastatin can be decreased when combined with Remacemide.
Mefloquine The therapeutic efficacy of Remacemide can be decreased when used in combination with Mefloquine.
Mianserin The therapeutic efficacy of Remacemide can be decreased when used in combination with Mianserin.
Orlistat Orlistat can cause a decrease in the absorption of Remacemide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Topotecan Remacemide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Remacemide.
Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Remacemide.
Alprazolam The metabolism of Alprazolam can be decreased when combined with Remacemide.
Warfarin The serum concentration of Warfarin can be increased when it is combined with Remacemide.
Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Remacemide.
(R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with Remacemide.
R,S-Warfarin alcohol The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Remacemide.
S,R-Warfarin alcohol The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Remacemide.
(S)-Warfarin The serum concentration of (S)-Warfarin can be increased when it is combined with Remacemide.
Midazolam The serum concentration of Midazolam can be increased when it is combined with Remacemide.
Tetracosactide The risk or severity of liver damage can be increased when Tetracosactide is combined with Remacemide.
Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Remacemide.
Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Remacemide.
Ethanol Remacemide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Remacemide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Remacemide.
Fluvoxamine The risk or severity of adverse effects can be increased when Remacemide is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Remacemide is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Remacemide is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Remacemide is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Remacemide is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Remacemide is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Remacemide is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Remacemide is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Remacemide is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Remacemide is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Remacemide is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Remacemide is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Remacemide is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Remacemide is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Remacemide is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Remacemide is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Remacemide is combined with Alaproclate.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Remacemide.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Remacemide.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Remacemide.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Remacemide.
Desipramine The risk or severity of CNS depression can be increased when Desipramine is combined with Remacemide.
Pizotifen The risk or severity of CNS depression can be increased when Pizotifen is combined with Remacemide.
Dosulepin The risk or severity of CNS depression can be increased when Remacemide is combined with Dosulepin.
Cocaine The risk or severity of methemoglobinemia can be increased when Remacemide is combined with Cocaine.
Quetiapine The risk or severity of CNS depression can be increased when Quetiapine is combined with Remacemide.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Remacemide.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Remacemide.
Doxepin The risk or severity of CNS depression can be increased when Doxepin is combined with Remacemide.
Terfenadine The metabolism of Terfenadine can be decreased when combined with Remacemide.
Clozapine The serum concentration of Clozapine can be increased when it is combined with Remacemide.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Remacemide.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Remacemide.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Remacemide.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Remacemide.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Remacemide.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Remacemide.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Remacemide.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Remacemide.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Remacemide.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Remacemide.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Remacemide.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Remacemide.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Remacemide.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Remacemide.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul